The DOI matches its Crossref record.
Endothelin-A Receptor Antagonism Reduces Blood Pressure and Increases Renal Blood Flow in Hypertensive Patients With Chronic Renal Failure: A Comparison of Selective and Combined Endothelin Receptor Blockade
Abstract
Background— Endothelin (ET) is implicated in the pathophysiology of chronic renal failure (CRF). We therefore studied the systemic and renal hemodynamic effects of ET receptor antagonists in CRF and examined differences between selective ETA, selective ETB, and combined ETA/B receptor blockade. Methods and Results— We conducted a randomized, placebo-controlled, double-blind, 4-way crossover study comparing selective ET receptor antagonists BQ-123 (ETA) and BQ-788 (ETB), given alone and in combination, in acute studies in 8 hypertensive CRF patients and 8 matched healthy controls. BQ-123, alone and in combination with BQ-788, reduced blood pressure in CRF, particularly with BQ-123 alone (mean arterial pressure: controls −4±2%, CRF −13±2%, P <0.01 versus placebo). In CRF, in the face of this fall in blood pressure, BQ-123 substantially increased renal blood flow (38.8±23.9%, P <0.01 versus placebo) and reduced renal vascular resistance (−44.5±11.3%, P <0.01 versus placebo) when given alone but not when combined with BQ-788. These changes were accompanied by a reduction in effective filtration fraction. BQ-123, alone or in combination with BQ-788, had minimal effects on the renal circulation in healthy controls, and BQ-788 alone produced both systemic and renal vasoconstriction in CRF and healthy controls. Conclusions— ETA receptor antagonism was highly effective in lowering blood pressure in CRF patients currently treated for hypertension. In addition, there were effects consistent with a renoprotective action. However, because the ETB receptor appears to play a key role in the maintenance of tonic renal vasodilation, combined ETA/B receptor antagonism, although it lowered blood pressure, did not confer these renal benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Self-citationThe importance of endothelin-1 for vascular dysfunction in cardiovascular disease
BOHM, F., & PERNOW, J. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.06.004 · Cited by 516
Regulation of Blood Pressure and Salt Homeostasis by Endothelin
Kohan, D. E., Rossi, N. F., Inscho, E. W., & Pollock, D. M. (2011) · Physiological Reviews · doi:10.1152/physrev.00060.2009 · Cited by 433
Endothelin and endothelin antagonists in chronic kidney disease
Kohan, D. E., & Barton, M. (2014) · Kidney International · doi:10.1038/ki.2014.143 · Cited by 307
Metadata
- Authors
- Goddard, J., Johnston, N. R., Hand, M. F., Cumming, A. D., Rabelink, T. J., Rankin, A. J., & Webb, D. J.
- Venue
- Circulation
- Published
- 2004-03-09
- Volume
- 109
- Issue
- 9
- Pages
- 1186-1193
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2074636215
- Cited by
- 194
- References
- 0
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endothelin-A Receptor Antagonism Reduces Blood Pressure and Increases Renal Blood Flow in Hypertensive Patients With Chronic Renal Failure: A Comparison of Selective and Combined Endothelin Receptor Blockade. https://app.cochat.ai/papers/10.1161/01.cir.0000118499.69469.51
- The paper
- Goddard, J., Johnston, N. R., Hand, M. F., Cumming, A. D., Rabelink, T. J., Rankin, A. J., & Webb, D. J. (2004). Endothelin-A Receptor Antagonism Reduces Blood Pressure and Increases Renal Blood Flow in Hypertensive Patients With Chronic Renal Failure: A Comparison of Selective and Combined Endothelin Receptor Blockade. Circulation. https://doi.org/10.1161/01.cir.0000118499.69469.51
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.